Side-by-side · Research reference
AdipotidevsLL-37
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BHuman-MechanisticHUMAN-REVIEWED15/35 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
01Mechanism of Action
Parameter
Adipotide
LL-37
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
—
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
LL-37
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
—
Frequency
Not specified in available data
—
Evidence basis
Preclinical animal models only
In vitro, animal models, human observational
Human data
None — no clinical trials reported
—
Endogenous expression
—
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
Exogenous (experimental)
—
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
LL-37
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
LL-37
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Cytotoxicity (high dose)
—
Membrane disruption in host cells at supraphysiological concentrations
Pro-inflammatory signaling
—
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
Theoretical cancer risk
—
Immunomodulatory roles in tumor microenvironment under investigation
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
LL-37
—Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
05Administration Protocol
Parameter
Adipotide
LL-37
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
—